Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (SG:T14) has released an update.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has conducted its 5th board meeting for FY2024, where they approved a significant capital injection into Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. The board, in full attendance, also sanctioned a resultant joint venture and a substantial guarantee provision, both contingent on the completion of the capital injection and classified as interested person transactions.
For further insights into SG:T14 stock, check out TipRanks’ Stock Analysis page.
